Soleno Therapeutics (SLNO) Price & Analysis

Compare

803 Followers

SLNO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$41.50 - $90.32

Previous CloseN/A

Volume118.06K

Average Volume (3M)1.43M

Market Cap

$3.60B

Enterprise Value$4.00B

Total Cash (Recent Filing)$286.84M

Total Debt (Recent Filing)$52.77M

Price to Earnings (P/E)―

Beta-0.70

Next Earnings

Nov 05, 2025

EPS Estimate

0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding53,145,008

10 Day Avg. Volume1,885,289

30 Day Avg. Volume1,427,393

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.11

Enterprise Value/Revenue122.34

Enterprise Value/Gross Profit125.01

Enterprise Value/Ebitda-22.34

Forecast

1Y Price Target

$119.56

Price Target Upside76.68% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

EarningsThe company delivered $32.7M in total net product sales, blowing past original forecast of only $1.7M.

Market LaunchVYKAT XR U.S. roll-out is ahead of schedule, raising the price target.

Product ApprovalVykat XR bucked the trend of clinical shortcomings in PWS by becoming the first-approved treatment for hyperphagia in this devastating genetic syndrome.

Bears Say

Market CompetitionThe absence of viable competitors in the foreseeable future presents an opportunity for Soleno, but also a challenge to maintain market dominance without competitive pressure.

Soleno Therapeutics News

Nu double upgraded, Novavax downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

11d ago

3 Best Stocks to Buy Now, 8/20/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

11d ago

HIVE

OPRA

Soleno Therapeutics initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Soleno Therapeutics (SLNO) with an Overweight rating and $123 price target The shares...

11d ago

SLNO

Soleno Therapeutics price target raised to $110 from $100 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $100 and keeps a...

13d ago

SLNO

Soleno Therapeutics price target raised to $120 from $115 at TD Cowen

TD Cowen raised the firm’s price target on Soleno Therapeutics (SLNO) to $120 from $115 and keeps a...

24d ago

SLNO

Soleno Therapeutics price target raised to $110 from $105 at Oppenheimer

Oppenheimer raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $105 and keeps an Outperform...

24d ago

SLNO

Soleno Therapeutics Engages Investors in Roadshow

Soleno Therapeutics ( ($SLNO) ) has issued an announcement. During August 18-19, 2025, Soleno Therapeutics‘ senior management participated...

13d ago

SLNO

Strong Buy Recommendation for Soleno Therapeutics: Promising Outlook and Impressive Sales Performance of VYKAT XR

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Soleno Therapeutics, boosting the price target to...

13d ago

SLNO

Soleno Therapeutics’ Earnings Call Highlights Success and Optimism

Soleno Therapeutics (($SLNO)) has held its Q2 earnings call. Read on for the main highlights of the call....

23d ago

SLNO

Soleno Therapeutics Reports Strong Q2 2025 Performance

Soleno Therapeutics ( ($SLNO) ) has released its Q2 earnings. Here is a breakdown of the information Soleno...

24d ago

SLNO

Strong Buy Recommendation for Soleno Therapeutics Driven by Impressive Vykat XR Launch and Market Demand

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Soleno Therapeutics. The associated price...

24d ago

SLNO

Tyler Van Buren Reaffirms Buy Rating with Increased Sales Projections and Price Target for SLNO

TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Soleno Therapeutics today and set a price...

1M ago

SLNO

Soleno Therapeutics price target raised to $121 from $105 at Baird

Baird analyst Brian Skorney raised the firm’s price target on Soleno Therapeutics (SLNO) to $121 from $105 and...

2M ago

SLNO

Soleno Therapeutics Announces Public Stock Offering

Soleno Therapeutics ( ($SLNO) ) has shared an announcement. On July 10, 2025, Soleno Therapeutics announced a public...

2M ago

SLNO

SLNO FAQ

What was Soleno Therapeutics Inc’s price range in the past 12 months?

Soleno Therapeutics Inc lowest stock price was $41.50 and its highest was $90.32 in the past 12 months.

What is Soleno Therapeutics Inc’s market cap?

Soleno Therapeutics Inc’s market cap is $3.60B.

When is Soleno Therapeutics Inc’s upcoming earnings report date?

Soleno Therapeutics Inc’s upcoming earnings report date is Nov 05, 2025 which is in 66 days.

How were Soleno Therapeutics Inc’s earnings last quarter?

Soleno Therapeutics Inc released its earnings results on Aug 06, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.453 by $0.363.

Is Soleno Therapeutics Inc overvalued?

According to Wall Street analysts Soleno Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Soleno Therapeutics Inc pay dividends?

Soleno Therapeutics Inc does not currently pay dividends.

What is Soleno Therapeutics Inc’s EPS estimate?

Soleno Therapeutics Inc’s EPS estimate is 0.05.

How many shares outstanding does Soleno Therapeutics Inc have?

Soleno Therapeutics Inc has 53,145,008 shares outstanding.

What happened to Soleno Therapeutics Inc’s price movement after its last earnings report?

Soleno Therapeutics Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.453. Following the earnings report the stock price went down -3.055%.

Which hedge fund is a major shareholder of Soleno Therapeutics Inc?

Currently, no hedge funds are holding shares in SLNO

Soleno Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-69.53%

Trailing 12-Months

Asset Growth

9.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Soleno Therapeutics Inc

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Soleno Therapeutics (SLNO) Earnings & Revenues

Historic Earnings Reports

SLNO Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a highly positive sentiment with the successful launch and strong initial uptake of Vykat XR. The company's robust financial position and broad payer coverage further underscore the positive outlook. However, there are some uncertainties regarding future revenue streams and the upcoming challenges in the European market.View all SLNO earnings summaries

SLNO Stock 12 Month Forecast

Average Price Target

$119.56

▲(76.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"$43","146":"$146","68.75":"$68.8","94.5":"$94.5","120.25":"$120.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$145.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":119.56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$119.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$106.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,68.75,94.5,120.25,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86,90.53846153846153,95.07692307692308,99.61538461538461,104.15384615384616,108.6923076923077,113.23076923076923,117.76923076923077,122.3076923076923,126.84615384615384,131.3846153846154,135.9230769230769,140.46153846153845,{"y":145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86,88.58153846153846,91.16307692307693,93.74461538461539,96.32615384615384,98.90769230769232,101.48923076923077,104.07076923076923,106.65230769230769,109.23384615384616,111.81538461538462,114.39692307692309,116.97846153846154,{"y":119.56,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86,87.53846153846153,89.07692307692308,90.61538461538461,92.15384615384616,93.6923076923077,95.23076923076923,96.76923076923077,98.3076923076923,99.84615384615384,101.38461538461539,102.92307692307692,104.46153846153847,{"y":106,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":49.2,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.63,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >